Latest Governance News

Avecho Biotechnology has ramped up recruitment in its pivotal Phase III insomnia trial and is advancing plans for regulatory approval and commercialization of its TPM®-enhanced CBD capsule, aiming to be the first over-the-counter CBD insomnia treatment in Australia.

Culpeo Minerals reports significant progress in copper exploration across Chile with promising drilling results and a strategic acquisition of the Jupiter Project.

Patagonia Lithium has reported a remarkable 319% increase in its lithium resource at its Argentine project, alongside plans for further drilling and a $2.68 million capital raise to fund ongoing exploration.

Noble Helium advances its flagship North Rukwa helium project with a significant resource upgrade, rig exit at no cost, and new funding from key insiders, positioning for a leaner, data-driven drilling campaign.

Appen Limited reported a mixed Q2 FY25 with a 6% revenue decline year-over-year, driven by a strong 77% surge in its China business that achieved profitability, while US market challenges persist. The company targets $10 million in cost savings to fuel future growth.

Emerald Resources NL reported steady gold output at its Okvau Mine while unveiling significant resource expansions at its Dingo Range and Memot projects, alongside clearing its debt.

Tlou Energy Limited’s latest quarterly cash flow report reveals a cautious financial position with A$2.74 million in available funding, supporting approximately 2.5 quarters of operations as exploration activities continue.

VanEck Global Defence ETF, launched in September 2024, has reported a solid AUD 2.8 million profit in its first interim financial results ending January 2025, marking a promising start for the defence-focused fund.

Mamba Exploration Limited has decided to restart gold exploration at its Ashburton Project in Western Australia, backed by a strategic review and a cash position of $579,000. Historical data points to promising high-grade gold targets, setting the stage for a detailed exploration program.

Noxopharm has initiated its HERACLES clinical trial for SOF-SKN, marking a key milestone for its Sofra platform, while deepening partnerships and actively seeking new funding to sustain development.

Atlas Arteria reported a robust 10.7% increase in Q2 2025 toll revenue, driven by strong traffic growth and toll hikes, while the French government reaffirmed its backing of the concession model with regulatory updates expected later this year.

DroneShield Limited has reported a record-breaking second quarter with revenues surging 480% year-on-year, underpinned by a robust $176 million in committed sales and a $2.3 billion pipeline. The company is aggressively expanding manufacturing and investing in next-generation counter-drone technologies to meet soaring global demand.